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Recent years have seen a growing interest in operational
research as a means to support improvements in health
care in low- and middle-income settings. In support of
global efforts to expand access to antiretrovirals, for
example, a substantial increase in operational research
activities has helped to deﬁne models of care that work
in resource-limited settings (Zachariah et al. 2012).
Reﬂecting the importance of these activities, operational
research has now become a standard track at interna-
tional AIDS conferences, (http://www.aids2012.org/
Default.aspx?pageId=477) and major HIV journals have
established sections dedicated to the publication of opera-
tional research ﬁndings (Anon 2010).
Yet, despite this rising appreciation of the contribution
of operational research to policy and practice, many still
view operational research as the ‘poor cousin’ of the
randomised trial. Traditional hierarchies of evidence
place case reports at the bottom of the pyramid and
randomised trials (or meta-analyses of trials) at the top.
While randomised trials may be the best way to come
close to an unconfounded estimate of the effect size of a
given intervention, they generally provide little informa-
tion about how to take an intervention to scale in a given
setting (Rawlins 2008).
Over the last few years, large randomised controlled
trials (RCTs) have shown convincing beneﬁcial effects of
artesunate over quinine to treat severe malaria, (Dondorp
et al. 2010) male medical circumcision to prevent HIV
infection (Siegfried et al. 2009) and limiting the use of
ﬂuid bolus in the management of paediatric septic shock
(Maitland et al. 2011). However, several years after
results of these trials were published, quinine remains the
standard of care in most high-malaria-burden countries,
(Ford et al. 2011) coverage of male medical circumcision
in southern Africa is below 10% in most high-burden
countries, (Njeuhmeli et al. 2011) and a year after the
publication of the trial results, guidelines for the manage-
ment of septic shock had yet to be revised in any Africa
country (Ehrhardt & Meyer 2012). The speed with which
RCT ﬁndings translate into a change in policy and prac-
tice depends on several factors, including limited
resources to fund a new intervention, feasibility, and the
values and preferences of policy makers, care providers
and patients.
From an epidemiological perspective, operational
research is riddled with confounding, biases, missing vari-
ables, and non-random sampling that make for highly
unreliable statistical inferences. Such concerns will lead
appraisers of evidence, using tools designed to assess
comparative drug efﬁcacy trials, to relegate operational
research to the bottom of the evidence quality pyramid.
The idea that operational research ﬁndings should be
regarded with scepticism is a view reinforced, perhaps
unintentionally, by guideline development tools such as
GRADE which rank evidence derived from observational
studies as being of low or very low quality (Guyatt et al.
2011a) (except in rare situations where studies show
large and consistent effects (Guyatt et al. 2011b)).
Programme implementers, however, have a different
perspective. When confronted with the results of a trial,
implementers will likely be far more concerned about
whether the intervention will work in their setting, with
their patient population and resource constraints, than
whether randomisation or allocation concealment was
carried out adequately (notwithstanding the importance
of such issues for trial design). For them, reports from
operational research can provide valuable insights that
are considered to be more reﬂective of ‘real life’ than the
results of randomised trials in which patients were care-
fully selected, staff were highly motivated and additional
resources were provided (Maher et al. 2012).
Operational research is therefore a critical step in the
pathway from new knowledge to improved outcomes.
Randomised trial data are important, for example, to
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antiretroviral therapy, while operational research will
help deﬁne the package of training and supervision
required to capacitate nurses in new clinical responsibili-
ties in different contexts. In this way, rather than viewing
operational research as the poor cousin of randomised
trials, the two approaches should be viewed as ‘relatives’,
which can cooperate very productively if done well.
Without a collective effort on the part of researchers,
funders and policy makers to integrate operational
research into their activities, there is a risk that many
years will continue to pass between the publication of
‘deﬁnitive’ trial results, and changes in policy and prac-
tice where it matters most.
The views expressed are those of the authors and
may not necessarily represent the views of the afﬁliated
organisations.
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